Bayesian Capital Management, LP United Therapeutics Corp Transaction History

Bayesian Capital Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$210.76 - $249.51 $708,153 - $838,353	3,360 New	3,360 $771,000
Q4 2022 Feb 14, 2023	BUY	$205.95 - $280.43 $317,574 - $432,423	1,542 New	1,542 $428,000
Q2 2022 Aug 15, 2022	BUY	$174.81 - $241.14 $1.36 Million - $1.88 Million	7,800 Added 458.82%	9,500 $2.24 Million
Q1 2022 May 16, 2022	BUY	$166.16 - $213.96 $282,472 - $363,732	1,700 New	1,700 $305,000
Q1 2020 May 15, 2020	SELL	$79.39 - $115.35 $208,081 - $302,332	-2,621 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$78.31 - $95.34 $205,250 - $249,886	2,621 New	2,621 $231,000
Q3 2019 Nov 13, 2019	SELL	$74.85 - $85.99 $926,343 - $1.06 Million	-12,376 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$76.06 - $120.81 $941,318 - $1.5 Million	12,376 New	12,376 $966,000
Q1 2018 May 15, 2018	SELL	$107.21 - $151.94 $493,166 - $698,924	-4,600 Closed	0 $0
Q4 2017 Feb 12, 2018	BUY	$118.58 - $151.28 $545,468 - $695,888	4,600	4,600 $681,000

672

42.4M

194K

295K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.5B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.